Philip Aschi, DO
Urology · Wilmington, OHNPI 1467463695
Payments from drug & device makers
Across 315 payments — averaging $36.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$4K
- Medtronic$2K
- Teleflex LLC$1K
- Neotract Inc.$1K
- Astellas Pharma US Inc$469
- Sumitomo Pharma America, Inc.$408
- plus $2K from 24 others
What the payments were for
- Travel & lodging$4384%
- Food & beverage$10,58293%
- Education$3093%
- Gifts$951%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 71 | $4,291 |
| Medtronic(2 entities) | 125 | $2,267 |
| Teleflex LLC | 12 | $1,383 |
| Neotract Inc. | 11 | $1,025 |
| Astellas Pharma US Inc | 21 | $469 |
| Sumitomo Pharma America, Inc. | 17 | $408 |
| Antares Pharma, Inc. | 12 | $233 |
| Endo Pharmaceuticals Inc. | 8 | $203 |
| Palette Life Sciences, Inc. | 1 | $162 |
| Johnson & Johnson | 5 | $149 |
| Progenics Pharmaceuticals, Inc. | 2 | $143 |
| Laborie Medical Technologies Corp. | 2 | $137 |
| Myovant Sciences Inc. | 2 | $110 |
| Tosoh Bioscience, Inc. | 1 | $95 |
| AbbVie(2 entities) | 3 | $46 |
| Bayer | 2 | $37 |
| Merck | 2 | $37 |
| Axonics, Inc. | 3 | $35 |
| Coloplast | 2 | $29 |
| Telix Pharmaceuticals | 1 | $24 |
| Dendreon Pharmaceuticals LLC | 1 | $23 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
| Blue Earth Diagnostics | 1 | $17 |
| Acerus Pharmaceuticals Corporation | 1 | $16 |
| Sagent Pharmaceuticals | 1 | $15 |
| Accord Healthcare, Inc. | 1 | $14 |
| Aytu Biopharma, Inc. | 1 | $13 |
| Pfizer | 1 | $12 |
| Clarus Therapeutics Inc. | 1 | $11 |
| Innovative Medical Technologies, LLC | 3 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$1,270
- AMS 700$1,161
- UroLift$1,104
- GENERAL ERECTILE DYSFUNCTION$732
- UroLift System$517
- Barrigel$427
- LithoVue$253
- GEMTESA$125
- PYLARIFY$124
- LITHOCLAST$119
- ADVANCE$107
- XIAFLEX$107
How this compares
$11,425 in reported general payments places this provider in the 75th percentile of 485 urology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 153 | $86,941 |
| MyrbetriqMirabegron | 81 | $59,322 |
| XyostedTestosterone Enanthate | 20 | $12,673 |
| Tamsulosin Hcl | 439 | $4,633 |
| Finasteride | 342 | $4,270 |
| Trospium Chloride | 32 | $1,852 |
| Testosterone Cypionate | 36 | $1,591 |
| Solifenacin Succinate | 27 | $1,494 |
| Potassium Citrate ErPotassium Citrate | 16 | $1,476 |
| Bicalutamide | 26 | $1,362 |
| Doxazosin Mesylate | 40 | $733 |
| Oxybutynin Chloride | 38 | $581 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 22 | $490 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 19 | $420 |
| NitrofurantoinNitrofurantoin Macrocrystal | 16 | $313 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $408 | $86,941153 claims |
| Astellas Pharma US IncMyrbetriq | $469 | $59,32281 claims |
| Antares Pharma, Inc.Xyosted | $233 | $12,67320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 485 urology providers in Ohio.
Other urology in Wilmington
- Marc PliskinCincinnati$20.8M
- Lawrence GervasiMiddleburg Heights$4.7M
- Martin FritzhandCincinnati$4.6M
- Kamal PoharCincinnati$3.4M
- Eric SingerColumbus$2.1M
- Benjamin MartinGahanna$1.1M
- Howard GoldmanCleveland$747K
- Jihad KaoukCleveland$696K
- Raymond RackleyCleveland$695K
- Sandip VasavadaCleveland$512K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.